236 related articles for article (PubMed ID: 6680403)
21. View from the Nation's Capital. Animal research: public pressure versus research needs.
Appler WD
J Clin Psychopharmacol; 1986 Oct; 6(5):305-8. PubMed ID: 3771815
[No Abstract] [Full Text] [Related]
22. Relative efficacy.
Stetler CJ
J Med Assoc Ga; 1972 Sep; 61(9):312-5. PubMed ID: 5080001
[No Abstract] [Full Text] [Related]
23. Orphan drug development for the treatment of rare chronic diseases.
Moore ES
Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218
[No Abstract] [Full Text] [Related]
24. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
25. View from the Nation's Capital. Investigational new drug (IND) and new drug application (NDA).
Romansky MA
J Clin Psychopharmacol; 1983 Jun; 3(3):193-4. PubMed ID: 6680405
[No Abstract] [Full Text] [Related]
26. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
27. View from the Nation's Capital. New drug application (NDA) and investigational new drug (IND) regulations.
Romansky MA
J Clin Psychopharmacol; 1983 Dec; 3(6):380-3. PubMed ID: 6680409
[No Abstract] [Full Text] [Related]
28. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
29. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
30. FDA's interferon-beta decision reignites orphan debate.
Marshall A
Nat Biotechnol; 1999 Apr; 17(4):324-5. PubMed ID: 10207871
[No Abstract] [Full Text] [Related]
31. View from the Nation's Capital. FDA moves forward (and backwards) on a number of simmering issues.
Appler WD
J Clin Psychopharmacol; 1988 Feb; 8(1):57-8. PubMed ID: 3351001
[No Abstract] [Full Text] [Related]
32. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
33. 1989 annual survey--133 orphan drug products.
Hosp Pharm; 1990 Apr; 25(4):367-71, 375-86. PubMed ID: 10104391
[No Abstract] [Full Text] [Related]
34. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
35. Development of orphan products.
FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406
[No Abstract] [Full Text] [Related]
36. King of the pill. Pfizer is the biggest drug company ever. Can it become the best?
Simons J
Fortune; 2003 Apr; 147(7):94-6, 100, 102. PubMed ID: 12698860
[No Abstract] [Full Text] [Related]
37. The Orphan Products Board of the Department of Health & Human Services.
Crooks GM
Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294
[No Abstract] [Full Text] [Related]
38. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
39. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1987 Jun; 7(3):185-6. PubMed ID: 3597806
[No Abstract] [Full Text] [Related]
40. Problems associated with developing orphan drugs into available therapy.
Van Woert MH
Prog Clin Biol Res; 1985; 197():171-3. PubMed ID: 4070291
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
